In a bid to promote new biopharmaceutical technologies in Nigeria, the National Biotechnology Research and Development Agency (NBRDA) says it is set to lead the initiative.
The agency made this known when it signed a Memorandum of Understanding (MoU) with La Shipson Pharmaceuticals Limited, a drug manufacturing company.
According to the Director General of NBRDA, Prof. Abdullahi Mustapha, in Abuja on Wednesday, the partnership would focus on the production of HIV antiretroviral and other essential drugs within Nigeria.
He said that the project would also generate job opportunities, create wealth, and improve healthcare service delivery across the country.
“By positioning our country as a hub for pharmaceutical innovation, we are taking significant steps towards reducing our reliance on foreign drug imports.
‘’The enhancement of our laboratory infrastructure coupled with technology transfer and capacity building will invigorate indigenous capacity in essential drug and vaccine production,’’ NBRDA D-G said.
Mr Godiya Shipi, the Chief Executive Officer (CEO) of La Shipson Pharmaceuticals Ltd., underscored the imperative of local production in addressing healthcare gaps in the country.
Also Read: NAFDAC Launches Mobile Technologies to Combat Counterfeit Medicines in Nigeria
Mr Handsome Momoh, the NBRDA Board Chairman said that the partnership would bridge the critical healthcare gap in Nigeria.
‘By localising production, the partnership would ensure access to life-saving drugs while empowering local workforce.
“As part of this collaboration, La Shipson will commence the production of HIV and other related drugs at NBRDA, where members of staff will engage in research and analysis.
”NBRDA and La Shipson Pharmaceuticals are poised to lead Nigeria toward a more self-sufficient and innovative healthcare future, ensuring that critical medications are produced locally and made accessible to Nigerians,’’ he said.
